Drug Trial Radar · NCT07286006
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
372
Planned (sponsor's estimate)
Start
Jan 26, 2026
Primary completion
Mar 2030
Study completion Mar 2030
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Conditions
- Graves' Disease
Interventions
IMVT-1402Drug
Dose 1 for up to 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402Time frame: At Week 52
Locations
131 sites in 11 countries. Site status is shown where the registry gives one.
Site Number - 1561
Phoenix, Arizona
Site Number - 1519
Phoenix, Arizona
Site Number - 1530
Tucson, Arizona
Site Number - 1510
Concord, California
Site Number - 1587
Huntington Beach, California
Site Number - 1554
Los Angeles, California
Site Number - 1588
Orange, California
Site Number - 1559
San Francisco, California
Site Number - 1558
Santa Clarita, California
Site Number - 1552
Torrance, California
Site Number - 1533
Aurora, Colorado
Site Number -1514
Englewood, Colorado
Site Number - 1516
Newark, Delaware
Site Number - 1567
Washington D.C., District of Columbia
Site Number - 1556
Clearwater, Florida
Site Number - 1522
Doral, Florida
Site Number - 1523
Hialeah, Florida
Site Number - 1581
Jacksonville, Florida
Site Number - 1582
Jacksonville, Florida
Site Number - 1505
Miami, Florida
Site Number - 1564
Miami, Florida
Site Number - 1591
Miami, Florida
Site Number - 1590
Ocoee, Florida
Site Number - 1508
Orlando, Florida
Site Number - 1507
Port Charlotte, Florida
Site Number - 1548
West Palm Beach, Florida
Site Number - 1566
Atlanta, Georgia
Site Number - 1526
Columbus, Georgia
Site Number - 1579
Macon, Georgia
Site Number - 1518
Stockbridge, Georgia
Site Number - 1562
Indianapolis, Indiana
Site Number - 1568
Kansas City, Kansas
Site Number - 1534
Topeka, Kansas
Site Number - 1571
Bowling Green, Kentucky
Site Number - 1580
Florence, Kentucky
Site Number - 1546
Louisville, Kentucky
Site Number - 1589
Metairie, Louisiana
Site Number - 1555
New Orleans, Louisiana
Site Number - 1565
Baltimore, Maryland
Site Number - 1557
Boston, Massachusetts
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.